Therapeutic Expertise

Cardiovascular

Our experienced team specialises in conducting cardiovascular clinical trials with a focus on reducing cardiovascular events, improving survival rates, and enhancing quality of life for patients.

Coronary artery diseaseHeart failureHypertension & arrhythmiasHyperlipidaemia

We focus on achieving endpoints such as reduced cardiovascular events, increased survival, and improved quality of life, working with independent experts who oversee trial safety and efficacy data.

Conducting a cardiovascular clinical trial demands meticulous planning, adherence to ethical standards, and rigorous methodology to generate meaningful, actionable results for improving patient care.

Addressing common pain points in cardiovascular clinical trials

Complex endpoint evaluation

Cardiovascular trials frequently use composite endpoints combining several outcomes, which can complicate trial design, analysis, and interpretation.

Cardiovascular solution — Advanced endpoint analysis

We employ sophisticated statistical techniques tailored for composite endpoints and offer consultation on endpoint selection to match trial objectives.

Diverse patient populations

Cardiovascular diseases are prevalent in diverse populations with varying genetic, lifestyle, and comorbidity factors, making a representative sample challenging.

Cardiovascular solution — Long-term patient engagement programs

We use patient engagement tools and programs to keep participants informed and motivated throughout the study, reducing attrition rates.

Long follow-up durations

Clinical outcomes might occur years after treatment, demanding prolonged follow-up and increasing the risk of data inconsistencies and drop-offs.

Cardiovascular solution — Centralised imaging and diagnostics

Our centralised imaging platform with standardised protocols and trained specialists ensures consistent techniques and improved data quality across sites.

Safety concerns with new interventions

New cardiovascular drugs or devices may carry unforeseen risks, emphasising the need for rigorous safety monitoring.

Cardiovascular solution — Rigorous cardio-specific safety protocols

Our specialised cardiovascular safety team, armed with cutting-edge monitoring technologies, focuses exclusively on cardiovascular risk factors and outcomes.

Resources

Cardiovascular clinical trial resources

Hypercholesterolemia

Diagnostic criteria, epidemiology, pivotal endpoints, and endpoint-determination challenges.

HFrEF

A detailed analysis of the epidemiology, pathophysiology, and regulatory landscape of HFrEF.

Pulmonary Arterial Hypertension

Diagnostic criteria, pathophysiology, and pivotal endpoints in PAH clinical trials.

Evidence & insights

Cardiovascular white papers

Open-access reports from our physicians and data science teams — free, no sign-in.

Frequently asked questions

Cardiovascular clinical trials — FAQs

What cardiovascular indications does iNGENū support?

Heart failure (including HFrEF), hypercholesterolemia, pulmonary arterial hypertension and broader cardiometabolic programmes, with appropriate imaging and endpoint expertise.

Can iNGENū manage the imaging and endpoint complexity of CV trials?

Yes — we combine a Central Reading Room, endpoint adjudication and physician oversight to standardise cardiovascular endpoints across sites.

Why run a cardiovascular trial in Australia?

TGA CTN approval can be as fast as ~4 weeks, the R&D Tax Incentive returns up to 43.5% of eligible spend, and the data is FDA-acceptable.

The iNGENū CRO difference

Australian expertise, direct FDA submission

We uniquely combine Australian expertise with direct FDA submission capabilities, offering a streamlined path for sponsors to achieve global approval. Trial data from Australia can be submitted directly to the FDA via our E-Gateway, eliminating the need for third-party intermediaries.

iNGENū takes a highly strategic and disciplined approach to clinical research, ensuring every dollar is directed toward generating meaningful outcomes — eliminating unnecessary costs while maintaining the highest scientific and regulatory standards across the Asia-Pacific region.

“We have been using iNGENū for a Phase 1, first-in-human trial of our investigational drug — medical writing, project management, clinical data management and full end-to-end execution and monitoring. We have been particularly impressed by the out-of-the-box creative solutions to speed up and reduce overheads during this clinical trial.”

Giles MossChief Executive Officer

Ready to discuss your Cardiovascular clinical trial?

Talk to our team about how iNGENū CRO can accelerate your research.

Request a proposal